Gallstones in acromegalic patients undergoing different treatment regimens.
The frequency of gallstones during long-term treatment with the somatostatin analogue octreotide reported in different studies varies from 0% to 50%, the reason for this variation being unknown. Therefore, we examined 58 acromegalic patients undergoing different treatment regimens for the frequency of gallstones. Thirteen were treated with octreotide, 20 with bromocriptine, and 25 had no medical treatment after successful neurosurgery. Also, 58 patients without known gallbladder disease served as controls. The postprandial gallbladder contraction was also investigated in 27 acromegalic patients (10 with octreotide, 10 with bromocriptine, and 7 with no medical therapy). Ten of the 58 acromegalic patients were found to have gallstones, 4 of 25 receiving no medical treatment, 4 of 20 treated with dopamine agonists, and 2 of 13 treated with octreotide. In 9 of the 58 control patients, gallstones were detected. Although in the octreotide group the gallstones were newly formed under therapy, there was no difference in gallstone prevalence between the different treatment regimens and the control group. However, the postprandial gallbladder contraction was significantly more often inhibited during octreotide therapy, and this effect was most pronounced during the first hours following injection. Differences in the timing of injections therefore may be an explanation of the variable incidence of cholelithiasis in the different studies.
Schmidt
K
K
KVB-Klinik, Königstein.
Leuschner
M
M
Harris
A G
AG
Althoff
P H
PH
Jacobi
V
V
Jungmann
E
E
Schumm-Draeger
P M
PM
Rau
H
H
Braulke
C
C
Usadel
K H
KH
D000172:Acromegaly / Q000150:complications / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use; D002765:Cholecystography; D002769:Cholelithiasis / Q000453:epidemiology / Q000209:etiology*; D004041:Dietary Fats / Q000494:pharmacology; D015259:Dopamine Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005704:Gallbladder / Q000000981:diagnostic imaging / Q000187:drug effects; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects; D015282:Octreotide / Q000009:adverse effects* / Q000627:therapeutic use; D015995:Prevalence; D014463:Ultrasonography
D004041:Dietary Fats; D015259:Dopamine Agents; D001971:Bromocriptine; D007334:Insulin-Like Growth Factor I; D015282:Octreotide